Navigation Links
Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry
Date:1/14/2009

NEW YORK, Jan. 14 /PRNewswire/ -- With all the woes of the U.S. economy, many people and businesses are looking to China for better opportunities. After all, China is expected to become the fifth-largest pharmaceutical market in the world by 2010. As the world watches, China is becoming a driving force in the pharmaceutical industry. People who want to be viable in this marketplace must learn to either thrive or die in this dynamic field.

But to survive and thrive overseas, you need the right tools. That's why interest is swelling in an exclusive Pharma China Seminar. The one-day seminar is being offered for three different dates and venues (New Jersey: February 26, 2009; Boston, MA: April 29, 2009; and San Francisco, CA: November 4, 2009).

In just one day, participants will be in the enviable position of learning everything they need to know (and have always wanted to know) about the Chinese Pharmaceutical Industry. This one-of-a-kind seminar is jampacked with the most recent, hard-to-find data, exclusive information, and real-world, on the ground experience you can't find anywhere else.

Momentum is building for this seminar, as participants say they're signing up to help solidify their roles as key players in the pharma industry's growth and expansion.

The following topics will be covered in-depth: regulatory structure, segmentation (hospital, ethical & OTC drugs, vaccines/bio, and others), environment and related issues; intellectual property/patent related issues; pricing and reimbursement/health insurance system; insights into various aspects of Chinese pharma including outsourcing (manufacturing, R&D, licensing/marketing/sales), API/intermediates sector, generic drugs, emerging Chinese global companies, IPOs/M&As/industry consolidation, and emerging pharma/biotech innovation; strategies and resources for market research and business intelligence; future growth drivers and risks, government commitment, opportunities and outlook; and much more!

Today, the spotlight is on the Chinese pharmaceutical industry. The world is looking at China for answers about what's next in pharmaceuticals. The Pharma China Seminar will offer key insight for participants fortunate enough to attend.

The sessions are interactive, and limited to only a small group of executives. That's why everyone is encouraged to register early to reserve their spot.

For more information, the detailed program agenda, or to register, please visit www.pharmachinaseminar.com


'/>"/>
SOURCE Pharma China Seminar
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cracking a tough nut for the semiconductor industry
2. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
3. Nikon Instruments Introduces Exclusive VAAS Detector Imaging Method for Confocal Microscopy
4. Exclusive Conference on Managing Your Online Brand: Shaping the Noise from the Blogosphere
5. Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts
6. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
7. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
8. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
9. Cryo-Cell Renews Upromise Industry-Exclusive Agreement
10. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
11. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):